NCT05858957

Magnesium Sulphate and Extubation Quality

Completed Phase 4 Last updated 17 January 2024

What this trial tests

Phase 4 trial testing Magnesium sulfate in Perioperative Complication in 98 participants. Completed in 30 July 2023.

Timeline

20 April 2023

Primary endpoint
15 July 2023

30 July 2023

Quick facts

Lead sponsor	Cukurova University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	98
Start date	20 April 2023
Primary completion	15 July 2023
Estimated completion	30 July 2023
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

• Magnesium sulfate — full drug profile →
• Saline

Conditions studied

• Perioperative Complication — all drugs for Perioperative Complication →

Sponsor

Cukurova University

Who can join

Adults 18 to 90, any sex, with Perioperative Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aimed to search effect of magnesium Sulfate on extubation quality scores, recovery and pain in larynx micro surgery. The patients allocated to two groups to receive magnesium sulfate 30 mg/kg in 100 ml saline infusion (maximum 2g) (Group m) or saline 100 ml (Group S) before induction of anesthesia. Anesthesia induction performed with propofol 2 mg/kg, rocuronium 0.6 mg/kg, remifentanil 0.5 µg/kg and general anesthesia maintained with total intravenous anesthesia (propofol 3-7 mg/kg, remifentanil 0.05-0.1 µg/kg/min and O2/air 30/70 mixture) to the all patients. Extubation quality scores, Extubation time, NRS scores were assessed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.